Providers/Grant Support
This activity is supported by an independent education grant from Lilly.
Credits Available
This activity does not offer credit.
Target Audience
This activity is designed to meet the educational needs of Imaging physicians, including Nuclear Medicine Physicians, Radiologists, Neuroradiologists, Radiology Physician Assistants, Imaging Residents. It is also suitable for Neurologists.
Program Overview
As the landscape of Alzheimer’s disease continues to evolve, PET imaging is playing an increasingly critical role in early and accurate diagnosis, disease staging, and treatment decision-making. But how can nuclear medicine and radiology physicians effectively integrate PET imaging into clinical practice while navigating regional variations, emerging tracers, and evolving guidelines?
This activity will cover the latest insights, practical strategies, and real-world case studies on PET imaging in Alzheimer’s disease. Featuring leading experts from Europe, Asia, and the USA, this program will provide a global perspective on best practices, challenges, and decision-making tools to optimize patient care.
Put your decision-making and interpretation skills into practice in a simulated environment. Presented with different patient characteristics, you will be challenged to choose the optimal tracer, accurately interpret the results, and advise on next steps.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Integrate best practice for the selection, interpretation, and reporting of PET biomarkers in the context of your local clinical practice
- Incorporate optimal communication and reporting methods to enhance interdisciplinary working and patient relationships
Faculty
Prof Jonathan E. McConathy
Professor and Director, Division of Molecular Imaging and Therapeutics
University of Alabama, Birmingham, USA
Jonathan McConathy, M.D., Ph.D., received a B.S. degree in Chemistry at the University of North Carolina at Chapel Hill. He then completed the Medical Scientist Training Program at Emory University with a Ph.D. in Neuroscience under the mentorship of Mark Goodman, Ph.D., and Michael Owens, Ph.D. He pursued postgraduate training at the Mallinckrodt Institute of Radiology (MIR) in St. Louis, Missouri through a residency in Diagnostic Radiology followed by a fellowship in Nuclear Medicine. Dr. McConathy then joined the faculty of MIR in July 2010 where he served as the Co-Director of the Radiology Research Residency.
Dr. McConathy joined UAB Department of Radiology in December 2015 and serves as the Director of the Division of Molecular Imaging and Therapeutics. In addition to clinical practice in Nuclear Medicine, he remains actively involved in the development and application of positron emission tomography (PET) tracers for oncology and neuroimaging as well as the use of simultaneous PET/MRI for both clinical indications and research.
His current research, clinical interests and area of expertise are multimodality molecular imaging including SPECT/CT, PET/CT and PET/MRI and PET tracer development and application for oncology and neuroimaging.
Disclosures of Conflicts of Interest
Prof Jonathan E. McConathy
Professor and Director, Division of Molecular Imaging and Therapeutics
Disclosures
Honoraria from Novartis, Telix, Eli Lilly/Avid; Consulting fees from GE Healthcare, Novartis; and research support from Eli Lilly/Avid, GE Healthcare. Other financial support from Clinical trial sponsors: Cytosite Biopharma, RayzeBio, Novartis, Telix, Fusion Pharmaceuticals, and Clarity Pharmaceuticals.
Instructions for Participation
There are no fees for participating in this enduring activity. Read the information and faculty disclosures, participate in this online activity, and submit the evaluation form.
Disclosure of Unlabeled Use
Faculty participating in any CME activity are required to disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For questions please contact [email protected]